Skip to main content
Signal8
Launch Terminal

Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Bicara Therapeutics Inc. Common Stock logo

Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAXHealthcare
-6.17%$9.13
AH$8.98-1.65%vs close
Mkt Cap$604.16M
Float43.17M
O/S66.17M
Vol
$ Vol
RVOL
Inst Own-
SI23.9%
Earnings
Dilution
Bicara Therapeutics Inc. Common Stock logoNASDAQ:BCAX$9.13-6.17%
Pipeline3 lead-sponsored trials·3 active0 completed(3 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Phase
  • Phase 2/3
    Recruiting

    FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

    Ficerafusp alfa, Pembrolizumab (KEYTRUDA®)

    Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

    Enrollment
    650
    Start
    Jan 2025
    Primary Completion
    Apr 2028est.
    Completion
    Jul 2029est.
    NCT06788990
  • Phase 2
    Recruiting

    A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC

    Ficerafusp alfa, Pembrolizumab (KEYTRUDA®)

    Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

    Enrollment
    160
    Start
    Sep 2026est.
    Primary Completion
    Mar 2028est.
    Completion
    Mar 2029est.
    NCT07807163
  • Phase 1
    Recruiting

    Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

    BCA101, Pembrolizumab

    Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal +9

    Enrollment
    473
    Start
    Jun 2020
    Primary Completion
    Oct 2027est.
    Completion
    Mar 2028est.
    NCT04429542
Search ClinicalTrials.gov for “Bicara Therapeutics”